TABLE 1

FROM:

Loss of BMI-1 expression is associated with clinical progress of malignant melanoma

Ingeborg M Bachmann, Hanne E Puntervoll, Arie P Otte and Lars A Akslen

Table 1. Associations between tumor cell expression of BMI-1, using two different antibodies, and important clinico-pathological variables and biomarkers in nodular melanomas

Variable	BMI-1 (F6) low a	BMI-1 (F6) high	P-value	BMI-1 (6C9) low	BMI-1 (6C9) high	P-value
Tumor thickness	4.0 mm	3.85 mm	NS	4.3 mm	3.7 mm	0.086b
Ulceration			NS			NS
Absent	46	19		32	15
Present	48	12		46	11
Necrosis			0.007c			0.006
Absent	58	28		44	23
Present	36	4		35	4
Mitotic countd	8.15/mm2	3.85/mm2	0.028d	8.6/ mm2	2.6/ mm2	0.024
Vascular invasion			NS			NS
Absent	72	25		56	23
Present	23	7		23	4
Ki-67 (% )	33	26	NS	35	25	0.020b
p14			0.001c			0.016
Weaka	47	5		39	6
Strong	47	25		39	20
p16			NS			NS
Weaka	46	18		44	11
Strong	48	14		35	16
p53			0.044c			NS
Absent	12	9		8	6
Present	82	23		71	21
CDK4			0.049c			0.004
Weaka	21	2		20	0
Strong	71	28		56	25
CyclinD1			NS			NS
Weaka	37	7		27	12
Strong	52	23		45	15
EZH2			NS			NS
Weaka	47	15		37	18
Strong	39	17		35	8
N-cadherin			0.004c			NS
Weaka	55	28		47	20
Strong	33	3		23	7
3 -Integrin			0.013c			0.009
Weaka	25	11		13	11
Strong	68	19		66	16
MVD/mm2	118.8	159.4	0.012f , b	125.00	143.75	NS

^a Cut-point median SI.

^b Mann–Whitney U-test.

^{c  2} test.

^d Mitoses/mm².